REMARKABLE
17.3.2020 14:02:06 CET | Business Wire | Press release
reMarkable today announced its next-generation paper tablet, reMarkable 2. The breakthrough device for note-taking and reviewing documents without distractions comes from the Norwegian developers behind the original paper tablet, which broke pre-order records during its 2017 launch.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005154/en/
reMarkable 2 is available for pre-order from reMarkable.com for €399, and is set to ship in June 2020. The limited-time launch offer will include a Marker and Folio.
At 0.19 in/4.7 mm thick, reMarkable 2 is the world’s thinnest tablet. Armed with weeks of battery life, and the breakthrough second-generation CANVAS display partially powered by E Ink technology, reMarkable 2 is the most paper-like digital device the industry has ever seen.
“reMarkable 2 supports our design philosophy of helping people think better through powerful technology,” said Magnus Wanberg, CEO of reMarkable. “Our latest tablet is paper-thin and our innovations in display technology make it so much like writing on paper that it’s hard to tell the difference.”
Inspired by paper, reMarkable 2 is a tool for note-taking, reading, and annotating documents without built-in distractions. “Today’s world is a frenzied place of ever-evolving technology that increasingly demands more of our time and attention. reMarkable 2 is a step in a more human-friendly direction. It’s designed to help people think,” said Wanberg.
The company has spent the last six years developing and perfecting its breakthrough paper tablet to deliver a realistic paper experience that supports improved focus and better thinking, while still maintaining a connection to the digital world.
reMarkable 2 features the ability to convert handwritten notes into text, along with options for organizing, sharing, annotating and searching documents. Among a host of other digital features, reMarkable’s cloud service makes content accessible through multi-platform companion apps for desktop and mobile. Its feature set is aimed at anyone who likes writing by hand, but wants to be able to reuse their work in their digital workflow.
At launch, reMarkable 2 will be accompanied by a Google Chrome plug-in that will allow users to read clean, reformatted web articles on their paper tablet without distractions.
Innovations in ultra-thin, high-friction surface materials and a completely redesigned, second-generation CANVAS display, make reMarkable 2 an unprecedented digital paper device. Millions of physical ink particles lift to the display’s surface, working in tandem with the high precision Marker to deliver exceptional paper-like accuracy.
A range of accessories to compliment reMarkable 2
All accessories are either included in their respective launch bundles, available as a bundle upgrade, or can be purchased separately later in the year when the pre-order finishes.
Markers:
reMarkable 2 will launch with two different Markers, both of which attach magnetically to the right side of the paper tablet:
Marker - €59 (included in pre-order)
Marker Plus (includes built-in eraser in the top end) - €99
Folios
: Folio and Book Folio have been created with function and style in mind. They’re both made from fine materials and designed to fit reMarkable 2 perfectly.
Folio - €79 - The original sleeve for reMarkable 2 (included in the first part of pre-order)
Book Folio - from €99 - Lets you keep your reMarkable 2 in its cover while working. Attaches magnetically to reMarkable 2
About reMarkable
Based in Oslo, Norway, reMarkable is the leading innovator within the paper tablet category, developing breakthrough digital paper tablets for note-taking, reading, and reviewing documents. Its vision is to create human-friendly products to help people think better. For more information about reMarkable and its digital paper tablet, visit https://remarkable.com
YouTube: https://youtu.be/0dgXuStEm4U
Instagram: https://www.instagram.com/remarkable/
Facebook: https://www.facebook.com/remarkableAS
Twitter: https://twitter.com/remarkablepaper
#remarkablepaper
View source version on businesswire.com: https://www.businesswire.com/news/home/20200317005154/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom